TY - JOUR
T1 - Expression of Epithelial-Mesenchymal Transition Markers in Treated Pancreatic Ductal Adenocarcinoma
AU - Wang, Minhua
AU - Estrella, Jeannelyn S.
AU - Katz, Matthew H.
AU - Kim, Michael
AU - Rashid, Asif
AU - Lee, Jeffrey E.
AU - Maitra, Anirban
AU - Wistuba, Ignacio I.
AU - Wolff, Robert A.
AU - Varadhachary, Gauri R.
AU - Wang, Huamin
N1 - Funding Information:
From the Departments of *Anatomical Pathology, †Surgical Oncology, ‡Translational Molecular Pathology, and §Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX. Received for publication May 20, 2019; accepted September 20, 2019. Address correspondence to: Huamin Wang, MD, PhD, Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Unit 085, 1515 Holcombe Blvd, Houston, TX 77030 (e‐mail: hmwang@mdanderson.org). M.W. and J.S.E. contributed equally to this work. This work was supported by the National Institutes of Health grant (1R01 CA196941). Parts of this study were presented as a poster at Annual Meeting of American Association for Cancer Research in Chicago, IL, 2018, and published as an abstract. The authors declare no conflict of interest. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/MPA.0000000000001432
Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Objectives Epithelial-mesenchymal transition (EMT) plays an important role in the progression, metastasis, and chemoresistance of pancreatic duct adenocarcinoma (PDAC); however, the expression of EMT markers and their clinical significance in PDAC patients who received neoadjuvant therapy (NAT) are unclear. Methods We examined the expression of EMT markers, including Zeb-1 (zinc finger E-box-binding homeobox 1), E-cadherin, and vimentin by immunohistochemistry in 120 PDAC patients who received NAT and pancreatectomy from 1999 to 2007. The results were correlated with clinicopathologic parameters and survival. Results Among 120 cases, 45 (37.5%) and 14 (11.7%) were positive for Zeb-1 and vimentin, respectively, and 25 (20.8%) were E-cadherin-low. The median overall survival and disease-free survival were 35.3 (standard deviation [SD], 2.8) and 15.9 (SD, 3.6) months, respectively, in vimentin-negative group compared with 16.1 (SD, 1.1) (P = 0.03) and 7.0 (SD, 1.1) months (P = 0.02) in the vimentin-positive group. In multivariate analysis, vimentin expression was an independent predictor of shorter disease-free survival (hazard ratio, 2.50; 95% confidence interval, 1.31-4.78; P = 0.016) and overall survival (hazard ratio, 2.55; 95% confidence interval, 1.33-4.89; P = 0.01). Conclusions Epithelial-mesenchymal transition markers are frequently expressed in treated PDAC. Vimentin expression is a prognostic biomarker for survival in PDAC patients who received NAT.
AB - Objectives Epithelial-mesenchymal transition (EMT) plays an important role in the progression, metastasis, and chemoresistance of pancreatic duct adenocarcinoma (PDAC); however, the expression of EMT markers and their clinical significance in PDAC patients who received neoadjuvant therapy (NAT) are unclear. Methods We examined the expression of EMT markers, including Zeb-1 (zinc finger E-box-binding homeobox 1), E-cadherin, and vimentin by immunohistochemistry in 120 PDAC patients who received NAT and pancreatectomy from 1999 to 2007. The results were correlated with clinicopathologic parameters and survival. Results Among 120 cases, 45 (37.5%) and 14 (11.7%) were positive for Zeb-1 and vimentin, respectively, and 25 (20.8%) were E-cadherin-low. The median overall survival and disease-free survival were 35.3 (standard deviation [SD], 2.8) and 15.9 (SD, 3.6) months, respectively, in vimentin-negative group compared with 16.1 (SD, 1.1) (P = 0.03) and 7.0 (SD, 1.1) months (P = 0.02) in the vimentin-positive group. In multivariate analysis, vimentin expression was an independent predictor of shorter disease-free survival (hazard ratio, 2.50; 95% confidence interval, 1.31-4.78; P = 0.016) and overall survival (hazard ratio, 2.55; 95% confidence interval, 1.33-4.89; P = 0.01). Conclusions Epithelial-mesenchymal transition markers are frequently expressed in treated PDAC. Vimentin expression is a prognostic biomarker for survival in PDAC patients who received NAT.
KW - E-cadherin
KW - Zeb-1
KW - epithelial-mesenchymal transition
KW - pancreatic ductal adenocarcinoma
KW - survival
KW - vimentin
UR - http://www.scopus.com/inward/record.url?scp=85074549271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074549271&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000001432
DO - 10.1097/MPA.0000000000001432
M3 - Article
C2 - 31688603
AN - SCOPUS:85074549271
SN - 0885-3177
VL - 48
SP - 1367
EP - 1372
JO - Pancreas
JF - Pancreas
IS - 10
ER -